BACKGROUND: Recent recognition of its broad pathophysiological importance has triggered an increased interest in 25-hydroxyvitamin D [25(OH)D]. By consequence, throughput in 25(OH)D testing has become an issue for clinical laboratories, and several automated assays for measurement of 25(OH)D are now available. The aim of this study was to test the accuracy and robustness of these assays by comparing their results to those of an isotope dilution/online solid-phase extraction liquid chromatography/tandem mass spectrometry (ID-XLC-MS/MS) method. We put specific focus on the influence of vitamin D-binding protein (DBP) by using samples with various concentrations of DBP.
Vitamin D sufficiency plays an important role not only in the prevention of osteoporosis or osteomalacia, but also, as suggested recently, in the prevention of other diseases such as cancer and autoimmune diseases (1) (2) (3) . Consequently, clinical laboratories receive numerous requests for measuring 25-hydroxyvitamin D [25(OH)D] 4 concentrations. Traditionally, assays for 25(OH)D have involved extraction with organic solvents, reconstitution of the specimen in a suitable matrix, and quantification by immunoassay (4, 5 ) . Alternative methods include HPLC (6 ) . Because such methods are rather laborious, automation of 25(OH)D measurements is desirable, and many automated methods have been developed recently.
A major challenge in measuring 25(OH)D is the displacement of 25(OH)D from vitamin D-binding protein (DBP). The organic solvents used to release 25(OH)D from its binding protein are not compatible with most immunoassays or protein-binding assays. Alternative methods for displacement have been devised, but it remains unclear whether the automated methods are sufficiently effective in liberating 25(OH)D from DBP (7) (8) (9) .
The aim of this study was to test the accuracy of the currently available 25(OH)D assays by comparing 6 available routine vitamin D assays with an isotope dilution/online solid-phase extraction liquid chromatography/tandem mass spectrometry (ID-XLC-MS/ MS) method, using plasma not only from healthy individuals, but also from patients with a broad range of DBP concentrations, to assess the sensitivity of the various assays to differences in circulating DBP concentrations.
Materials and Methods

SAMPLES
We obtained EDTA-plasma and serum from leftover material. Blood for plasma and serum was drawn from 51 healthy individuals, 52 pregnant women, 50 hemodialysis patients, and 50 intensive care (IC) patients. The male/female ratios and age ranges of these 4 participant groups were 23/28 and 20 -64 years, 0/52 and 19 -40 years, 24/26 and 33-89 years, 28/22 and 18 -89 years, respectively. All samples were handled identically. After centrifugation, plasma and serum were aliquoted and frozen at Ϫ20°C until blinded analysis took place. Storage time of specimens did not exceed 2 months. Only EDTA-blood was drawn from IC patients. Plasma and serum from pregnant women came from prenatal screening (9 -14 weeks of pregnancy). Blood from hemodialysis patients was drawn just before the start of their regular dialysis turn. 3 at concentrations ranging from 0 -100 g/L (0 -400 nmol/L) and IS at a fixed concentration. Limit of quantitation (LOQ) was 1.6 g/L (4.0 nmol/L), intraassay CV was Ͻ6%, and interassay CV was Ͻ8% for 3 concentrations between 10 and 72 g/L (25 and 180 nmol/ L). We established the accuracy of 25-hydroxyvitamin D results by measuring the standard and a control with a reference method (10 ) 270910MP). One assay was a RIA preceded by extraction (Diasorin; lot no. 125783C). Analyses on iSYS, Liaison, and Modular were performed at Medial Diagnostic Centers, and analyses on Architect, Centaur, and the RIA were performed at the Endocrine Laboratory of the VU University Medical Center.
METHODS
ID-XLC-MS/MS. All 25(OH)D measurements by ID-XLC-MS/MS
All analyses were performed in EDTA plasma except the analyses on the iSYS, which were performed in serum, as the assay is not appropriate for plasma, according to the manufacturers.
Interassay CVs were Ͻ8%, Ͻ10%, Ͻ8%, Ͻ8%, Ͻ13%, and Ͻ11% for 3 concentrations between 10 and 44 g/L (25 and 110 nmol/L) using the Architect, Centaur, iSYS, Liaison, Modular, and RIA, respectively.
All 6 routine assays are competitive assays, where 25(OH)D in the sample competes with labeled 25(OH)D for binding to assay specific antibodies or-in the case of the Elecsys Vitamin D total assay-to recombinant DBP.
DBP assay. We measured DBP concentrations in EDTA-plasma using ELISA (R&D Systems). Intraassay variation was 4.3% at 249 g/mL.
Statistics. All 25(OH)D concentrations measured by routine assays were, within patient groups, compared to concentrations measured by ID-XLC-MS/MS. We calculated correlation coefficients (Pearson) and Passing-Bablok regression. 25(OH)D and DBP concentrations were nonparametrically compared between patient groups. All statistical analyses were performed using MedCalc. P values Յ0.05 were considered to reflect statistical significance.
Results
In only 11 of the 203 study participants (5 healthy individuals, 1 IC patient, 2 pregnant women, and 3 dialysis patients) was 25(OH)D 2 detectable by ID-XLC-MS/MS. Concentrations of 25(OH)D 2 in these individuals were between 1.2 and 6 g/L (3 and 15 nmol/L). In these cases, 25(OH)D 2 and 25(OH)D 3 concentrations were added to reflect the total 25(OH)D concentration, which was then used for comparison to the 6 25(OH)D assays. Table 1 (Fig. 2) . The correlation and correlation coefficient between the DBP concentration and the deviation of each method from the ID-XLC-MS/MS method are shown in Fig. 3 .
Discussion and Conclusion
Major differences were found between 25(OH)D concentrations as measured by the various 25(OH)D assays tested in this study.
The differences observed suggest that there might be a standardization problem for some of the 25(OH)D assays. Recently, the group of Thienpont published a candidate reference method that allows manufacturers and laboratories to calibrate their method (10 ) and was used to check standardization of the ID-XLC-MS/MS method used in this study.
In the Centaur assay, a concentration-dependent difference (measuring falsely high in the low concentration range and falsely low in the high concentration range) is seen in all patient groups. As the Centaur assay was introduced very recently, no data were available about this assay in the literature. A subset of the measurements were repeated with the help of Siemens Diagnostics, which confirmed the data. Other assays also showed such a concentration-dependent difference in the dialysis patient group. According to Siemens Diagnostics, new Centaur 25(OH)D reagents with an adjustment to the low end will be released shortly.
Regression analysis also revealed significant differences in results between the various patient groups. We hypothesized that variations in DBP concentrations between these patient groups were the cause for the observed differences. Pregnant women, because of the estrogendependent production of DBP, have increased DBP concentrations (11) (12) (13) , a finding that was reconfirmed in our study. Pregnant women also showed, on average, higher 25(OH)D concentrations than our healthy controls, as measured by ID-XLC-MS/MS. These higher concentrations might be caused by the higher concentrations of DBP in pregnant women, but could also be due to vitamin D supplementation that is advised for pregnant women (14 ) .
Critically ill patients with sepsis and organ dysfunction have lower DBP concentrations (15, 16 ) , which was in agreement with our data. These decreased DBP concentrations might be a factor causing a significantly decreased mean 25(OH)D concentration in IC patients (measured with ID-XLC-MS/MS).
DBP is a highly polymorphic serum protein with 3 common alleles and Ͼ120 rare variants. We measured DBP concentration and did not make a distinction between the different forms of DBP. The various forms of DBP might have different affinity for 25(OH)D, resulting in variation in binding affinity in the plasma samples studied, that in theory might lead to the more extreme differences in people with variants. However, whether the binding affinity is different among the DBP variants is still a matter of debate (17) (18) (19) (20) .
Although the possibility that variations in DBP concentration might be problematic for automated 25(OH)D assays has been discussed, this is the first study that shows an inverse relationship between DBP concentrations and deviations of measured 25(OH)D concentrations from ID-XLC-MS/MS results for all 4 fully automated immunoassays tested. It appears that in these fully automated assays, not all 25(OH)D is extracted from the DBP in sera that have a relatively high DBP concentration. Such incomplete extraction leads to falsely low 25(OH)D concentration results. The fully automated Roche assay and the RIA that were also investigated in this study did not show such DBP concentration-dependent differences compared to the ID-XLC-MS/MS results. In the case of the RIA, this might be explained by the thorough extraction procedure preceding the RIA.
Taken together, our data suggest that not all assays are suitable for measuring 25(OH)D in all patient groups.
The DBP concentrations in our hemodialysis patient group did not differ from those in the group with healthy individuals, which is in accord with other data in the literature (21 ) . Despite DBP concentrations within the reference interval, however, most routine assays yielded 25(OH)D concentrations differing from those obtained with the ID-XLC-MS/MS in this hemodialysis patient group. Noteworthy is that the regression analysis of data in this patient group for all investigated assays had slopes that significantly differed from 1.00. We can only speculate about the cause of these deviations. Urea, for instance, could interfere with the release of 25(OH)D from its binding protein, with the equilibrium of 25(OH)D binding or with the reagents of the assay. Further studies have to be performed to clarify this issue.
In addition to the issue of releasing 25(OH)D from its binding protein, the differential cross-reactivity of 25(OH)D 3 and 25(OH)D 2 in immunoassays and protein-binding assays is a potential problem (7, 9 ) . However, as 25(OH)D 2 is not commonly used for dietary supplementation in our region, only very few of the tested samples contained 25(OH)D 2 . This potential problem therefore did not play a role in the differences that were observed between the assays in our study.
The question remains whether the observed differences in 25(OH)D measurements among different 25(OH)D assays are of clinical significance. Our study points to the importance of the 25(OH)D assay when choosing a cutoff for deficiency or insufficiency, as the percentage of vitamin D-sufficient and -insufficient people is critically dependent on the assay. For in- Clinical chemistry laboratories should be aware of the analytical problems in currently available 25(OH)D assays and be critical when introducing a new assay. Also physicians, researchers, reviewers, and authorities who provide advice on cutoffs for sufficiency and supplementation of 25(OH)D should carefully consider the 25(OH)D assay used in studies, before any conclusions are drawn or decisions made.
In conclusion, some of the assays used to measure 25(OH)D are not well standardized and report significantly different results from measurements performed with ID-XLC-MS/MS. The deviations, which are sometimes serious, are different in various patient groups and are dependent on the concentration of DBP and other still-unknown interfering factors.
